Company: CRL
Filing Date: 2025-04-02
Form Type: DEF 14A
Source: 0001104659-25-030908
Chunk: 25

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-04-02
Form: DEF 14A
Chunk 25
---
 January 2024.

24

(2) Reflects the aggregate dollar amount of all fees paid for services as a director, including annual retainer fees, committee, and/or committee chair fees. A description of the applicable fees can be found in the narrative below this table. For the following directors, each elected to receive all of their cash retainers in the form of an equivalent value of restricted stock units (RSUs) instead of cash: Mr. Bertolini, Ms. Kemps-Polanco, Mr. Llado, Dr. Mackay, and Mr. Wallman. (3) Amounts reflect (a) the grant date fair value of the RSUs granted to directors in fiscal year 2024 as part of their annual equity grant in May 2024, and (b) RSUs granted to Ms. Kemps-Polanco in connection with her joining the Board in January 2024, in all instances computed in accordance with Financial Accounting Standards Board Accounting Standards Codification (FASB ASC) Topic 718. See Item 8 “Financial Statements and Supplementary Data—Note 1 to our Consolidated Financial Statements” and Item 8 “Financial Statements and Supplementary Data—Note 15 to our Consolidated Financial Statements” included in our Annual Report on Form 10-K for the fiscal year ended December 28, 2024, for a discussion of the assumptions used by us in the Black-Scholes valuation model. As of December 28, 2024, each then current director held the aggregate number of unvested RSUs as follows: Dr. Andrews—559 Mr. Bertolini—953, Ms. Kemps-Polanco—844, Dr. Kochevar— 559, Mr. Llado—865, Dr. Mackay—931 Mr. Massaro—559, Dr. Thompson—559, Mr. Wallman— 1,019, and Ms. Wilson—559. (4) Amounts reflect (a) the grant date fair value of directors’ stock options granted in fiscal year 2024 as part of their annual equity grant in May 2024, and (b) stock options granted to Ms. Kemps-Polanco in connection with her joining the Board in January 2024, in all instances computed in accordance with FASB ASC Topic 718, and calculated using the Black-Scholes valuation model utilizing our assumptions. See Notes 1 and 15 to our Consolidated Financial Statements in our Annual Report on